ANGPT1 and myelodysplastic syndrome: Recent studies demonstrated that ANGPT-1 is overexpressed in MDS HSPCs and that high ANGPT1 expression is associated with worse clinical outcomes in high-risk MDS and AML patients (Cheng et al., 2011).